ClinicalTrials.gg
TerminatedNCT00479258Updated Oct 1, 2018Results posted

Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents

A Phase 3 interventional study of Inhaled insulin (Exubera) and Subcutaneous Insulin (subject's prescribed) in Diabetes Mellitus, Type 1, sponsored by Pfizer. Terminated at 1 site in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-10-01.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing insulin in Diabetes Mellitus, Type 1 — 4 open to participants now, 4 under way, none of them phase 3. Insulin · Diabetes Mellitus, Type 1.

Enrollment
46th of 51
2 · median 20
Started
2007
with 3 others
Phase 3
7 of 51
none open now
Registered
8th of 51
by date
Lead sponsor
3 of 51
Pfizer

Among the 51 studies testing insulin in Diabetes Mellitus, Type 1, this one is the 46th largest by enrollment, is one of 4 that started in 2007, is one of 7 in phase 3, and was the 8th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 51 studies testing insulin in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing insulin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.

Read the detailed description

Pfizer announced in October 2007 that it would stop marketing Exubera. At that time recruitment for the pediatric study, A2171083, was placed on hold. Two subjects completed the informed consent/assent process and entered the A2171083 study but none received treatment. The first subject withdrew consent during the Baseline Run-in period which was prior to Randomization. The second subject screen failed at Visit 1. After this time, Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171083 was terminated and no further recruitment took place.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with Type 1 diabetes mellitus for more than 6 months.
  • Males and females ages 6 to 17 years.
  • Subjects should be receiving, or be able to tolerate, at a minimum a 3 unit pre prandial dose of short acting subcutaneous insulin.

Exclusion criteria

Exclusion Criteria:

  • Subjects using an insulin pump
  • Smoking
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Inhaled insulin (Exubera)

    Drug: Inhaled insulin (Exubera)

  • Active comparator
    Subcutaneous Insulin (subject's prescribed)

    Drug: Subcutaneous Insulin (subject's prescribed)

Interventions

06

What researchers measure

Primary outcomes

  1. To Assess Pulmonary Safety and Glycemic Control of Exubera Over a 12 Month Controlled Period

    No subjects were dosed therefore no data collected.

    Time frame: 12 months

Secondary outcomes

  1. Change From Baseline in Other PFT Parameters

    Time frame: 12 months

  2. Slope From Baseline to Week 52 and Slope From Week 12 to Week 52 for FEV1 and FVC as a Percent of Predicted;

    Time frame: 12 months

  3. Treatment Preferences.

    Time frame: 12 months

  4. Change From Baseline in FVC

    Time frame: 12 months

  5. Slope for Other PFT Parameters;

    Time frame: 12 months

  6. Proportion of Subjects Achieving ADA Age Appropriate Guidelines for HbA1c

    Time frame: 12 months

  7. Change From Baseline in Insulin Antibodies (microU/mL);

    Time frame: 12 months

  8. Change From Baseline in Body Weight (kg), Height (cm), and Body Mass Index (BMI; kg/m2) and z Score (%);Dose of Insulin;

    Time frame: 12 months

  9. Hypoglycemic Event Rates;

    Time frame: 12 months

  10. 7 Point Home Glucose

    Time frame: 12 months

07

Results

Posted Nov 2, 2008
Limitations and caveats
Pfizer announced Oct07 it would stop marketing Exubera; recruitment placed on hold. Nektar, from which Pfizer licensed Exubera, announced April 9, 2008 it had stopped its search for a new marketing partner. Study terminated; no further recruitment.

Participant flow

Two subjects completed the informed consent/assent process and entered the A2171083 study but none received treatment. The first subject withdrew consent during the Baseline Run-in period which was prior to Randomization. The second subject screen failed at Visit 1. Location = UNITED STATES.

Participant flow — Overall Study
MilestoneInhaled Insulin (Exubera)Subcutaneous Insulin (Subject's Prescribed)
Started00
Completed00
Not completed00

Outcome measures

PrimaryTo Assess Pulmonary Safety and Glycemic Control of Exubera Over a 12 Month Controlled Period

No subjects were dosed therefore no data collected.

Time frame:
12 months

No measurements were reported for this outcome.

SecondaryChange From Baseline in Other PFT Parameters
Time frame:
12 months

Results for this outcome have not been posted.

SecondarySlope From Baseline to Week 52 and Slope From Week 12 to Week 52 for FEV1 and FVC as a Percent of Predicted;
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryTreatment Preferences.
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in FVC
Time frame:
12 months

Results for this outcome have not been posted.

SecondarySlope for Other PFT Parameters;
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryProportion of Subjects Achieving ADA Age Appropriate Guidelines for HbA1c
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Insulin Antibodies (microU/mL);
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Body Weight (kg), Height (cm), and Body Mass Index (BMI; kg/m2) and z Score (%);Dose of Insulin;
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryHypoglycemic Event Rates;
Time frame:
12 months

Results for this outcome have not been posted.

Secondary7 Point Home Glucose
Time frame:
12 months

Results for this outcome have not been posted.

Baseline characteristics

Age, Customized
Age, Customized(subjects)Inhaled Insulin (Exubera)Subcutaneous Insulin (Subject's Prescribed)Total
Sex: Female, Male
Sex: Female, MaleInhaled Insulin (Exubera)Subcutaneous Insulin (Subject's Prescribed)Total
Female———
Male———
08

Study locations

1 site
  • Pfizer Investigational Site
    Buffalo, New York 14222, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2008, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2007
First posted
May 28, 2007
Start
Oct 2007
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results first posted
Nov 2, 2008
Last update
Oct 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00479258
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 28, 2007
Start date
Oct 2007
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
Nov 2, 2008
Last update
Oct 1, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion